BLADE AIR MOBILITY INC C/WTS 07/05/2026 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 70.8 M

Revenue: As of FY2025 Q2, the actual value is USD 70.8 M.

EPS: As of FY2025 Q2, the actual value is USD -0.05.

EBIT: As of FY2025 Q2, the actual value is USD -3.722 M.

Passenger Segment

• Revenue: For the three months ended June 30, 2025, Passenger revenue was $25.7 million, a decrease of 13.2% from $29.6 million in 2024. For the six months ended June 30, 2025, Passenger revenue was $44.1 million, a decrease of 2.3% from $45.1 million in 2024.
• Adjusted EBITDA: Improved by $1.6 million for the three months ended June 30, 2025, from $0.8 million in 2024 to $2.4 million in 2025. For the six months ended June 30, 2025, Adjusted EBITDA improved by $4.3 million from - $1.9 million in 2024 to $2.4 million in 2025.

Medical Segment

• Revenue: For the three months ended June 30, 2025, Medical revenue was $45.1 million, an increase of 17.6% from $38.3 million in 2024. For the six months ended June 30, 2025, Medical revenue was $81.1 million, an increase of 9.0% from $74.4 million in 2024.
• Adjusted EBITDA: Increased by $0.5 million for the three months ended June 30, 2025, from $5.5 million in 2024 to $6.0 million in 2025. For the six months ended June 30, 2025, Adjusted EBITDA increased by $0.2 million from $9.9 million in 2024 to $10.1 million in 2025.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $3.3 million for the six months ended June 30, 2025, compared to $7.1 million for the same period in 2024.
• Investing Cash Flow: Net cash provided by investing activities was $49.1 million for the six months ended June 30, 2025, compared to $7.7 million for the same period in 2024.
• Financing Cash Flow: Net cash used in financing activities was $5.4 million for the six months ended June 30, 2025, compared to $1.2 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Blade Air Mobility, Inc. plans to leverage its asset-light business model to facilitate a transition to Electric Vertical Aircraft (EVA), aiming for lower cost air mobility that is quiet and emission-free. The company is also focusing on expanding its MediMobility Organ Transport services and enhancing its technology platform to support growth.
• Non-Core Business: The company announced the sale of its Passenger business to Joby Aviation, Inc., with the transaction expected to qualify as a discontinued operation. The sale is anticipated to provide up to $125 million in cash or shares, with $90 million received upon closing, subject to adjustments and holdbacks.